Maryland PDAB Gives Thumbs Up To Cost Reviews For Six Drugs

By Luke Zarzecki / May 20, 2024 at 6:05 PM
Updated Story Maryland’s prescription drug affordability board (PDAB) voted Monday (May 20) to move forward with cost review studies for six drugs, including the blockbuster drug for diabetes and obesity Ozempic. The drugs are AbbVie’s Skyrizi, Eli Lilly’s Trulicity, Novo Nordisk’s Ozempic, Boehringer Ingelheim’s Jardiance, AstraZeneca’s Farxiga, and Sanofi’s Dupixent, with the cost review of Dupixent scheduled to come after the others. Senate Bernie Sanders (I-VT), chair of the Senate health committee, is campaigning to lower the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.